The President of Alignment Healthcare directly sold 30,000 shares for a transaction value of ~$626,000 on April 15, 2026.
This sale represented ~2.83% of the insider's direct holdings, reducing direct ownership to 1,028,813 shares.
Only direct shares were transacted; no indirect or derivative activity was involved.
Sale cadence and transaction size are consistent with prior routine 10b5-1 plan activity, reflecting systematic portfolio management as holdings capacity declines.
Dawn Christine Maroney, President of Alignment Healthcare (NASDAQ:ALHC), reported the sale of 30,000 shares of common stock in an open-market transaction on April 15, 2026, according to a SEC Form 4 filing.
| Metric | Value |
|---|---|
| Shares sold (direct) | 30,000 |
| Transaction value | $626,199 |
| Post-transaction shares (direct) | 1,028,813 |
| Post-transaction value (direct ownership) | $21.5 million |
Transaction value based on SEC Form 4 reported price ($20.87); post-transaction value based on April 15, 2026, market close ($20.92).
| Metric | Value |
|---|---|
| Revenue (TTM) | $3.95 billion |
| Net income (TTM) | -$0.98 million |
| Employees | 1,679 |
| 1-year price change | 16.34% |
* 1-year price change calculated as of April 15, 2026.
Alignment Healthcare, Inc. is a technology-driven healthcare company specializing in Medicare Advantage plans, with a focus on providing personalized care to seniors. The company differentiates itself through a consumer-centric platform that integrates data analytics and care coordination to improve member outcomes and operational efficiency. Its strategic presence in select U.S. markets and emphasis on value-based care position it competitively in the healthcare plans industry.
Everyday investors shouldn’t look at Maroney’s recent transaction as a sign she’s losing confidence in Alignment Healthcare’s business. In fact, the recent reduction in scheduled share sales following a surging stock price suggests she expects further gains ahead.
Alignment Healthcare will announce first-quarter 2026 results on Thursday, April 30, after the market closes. Investors are hoping the company can repeat the outstanding results it reported at the end of 2025. Full-year revenue surged 46.1% year over year to $3.95 billion. Management confidently guided 2026 revenue to a range between $5.14 billion and $5.19 billion. The guidance range implies a 30% to 31% gain this year.
Instead of the deep losses that the company has consistently reported, Alignment Healthcare’s bottom line is approaching positive territory. It narrowed its fourth-quarter net loss to $11 million on a GAAP basis. With margins improving rapidly, selling Alignment Healthcare shares right now doesn’t seem like a wise move.
Before you buy stock in Alignment Healthcare, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Alignment Healthcare wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $524,786!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,236,406!*
Now, it’s worth noting Stock Advisor’s total average return is 994% — a market-crushing outperformance compared to 199% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of April 20, 2026.
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.